CN103709154B - 苯并咪唑衍生物及其制备方法和医药用途 - Google Patents
苯并咪唑衍生物及其制备方法和医药用途 Download PDFInfo
- Publication number
- CN103709154B CN103709154B CN201310042669.2A CN201310042669A CN103709154B CN 103709154 B CN103709154 B CN 103709154B CN 201310042669 A CN201310042669 A CN 201310042669A CN 103709154 B CN103709154 B CN 103709154B
- Authority
- CN
- China
- Prior art keywords
- base
- methyl
- oxo
- diazole
- benzimidazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CCC(C)*C(*)N(C)*C(C)=*(C=C)N Chemical compound CCC(C)*C(*)N(C)*C(C)=*(C=C)N 0.000 description 6
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (7)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510617905.8A CN105237527B (zh) | 2012-09-28 | 2013-02-04 | 苯并咪唑衍生物及其制备方法和医药用途 |
CN201510616496.XA CN105153141B (zh) | 2013-02-04 | 2013-02-04 | 苯并咪唑衍生物及其制备方法和医药用途 |
CN201310042669.2A CN103709154B (zh) | 2012-09-28 | 2013-02-04 | 苯并咪唑衍生物及其制备方法和医药用途 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210367692 | 2012-09-28 | ||
CN2012103676924 | 2012-09-28 | ||
CN201210367692.4 | 2012-09-28 | ||
CN201310042669.2A CN103709154B (zh) | 2012-09-28 | 2013-02-04 | 苯并咪唑衍生物及其制备方法和医药用途 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510616496.XA Division CN105153141B (zh) | 2013-02-04 | 2013-02-04 | 苯并咪唑衍生物及其制备方法和医药用途 |
CN201510617905.8A Division CN105237527B (zh) | 2012-09-28 | 2013-02-04 | 苯并咪唑衍生物及其制备方法和医药用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103709154A CN103709154A (zh) | 2014-04-09 |
CN103709154B true CN103709154B (zh) | 2016-06-15 |
Family
ID=50402543
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310042669.2A Active CN103709154B (zh) | 2012-09-28 | 2013-02-04 | 苯并咪唑衍生物及其制备方法和医药用途 |
CN201510617905.8A Active CN105237527B (zh) | 2012-09-28 | 2013-02-04 | 苯并咪唑衍生物及其制备方法和医药用途 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510617905.8A Active CN105237527B (zh) | 2012-09-28 | 2013-02-04 | 苯并咪唑衍生物及其制备方法和医药用途 |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN103709154B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105237527A (zh) * | 2012-09-28 | 2016-01-13 | 武汉朗来科技发展有限公司 | 苯并咪唑衍生物及其制备方法和医药用途 |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105622595A (zh) * | 2014-11-21 | 2016-06-01 | 重庆朗天制药有限公司 | 一种阿奇沙坦酯钾盐及其中间体新的制备方法 |
WO2016145622A1 (zh) * | 2015-03-18 | 2016-09-22 | 武汉朗来科技发展有限公司 | 苯并咪唑衍生物及其制备方法和医药用途 |
CN106032378B (zh) * | 2015-03-20 | 2019-10-25 | 武汉启瑞药业有限公司 | 新型arb化合物及其用途 |
CN107400122B (zh) | 2016-05-20 | 2020-10-23 | 武汉朗来科技发展有限公司 | 化合物及其制备方法、组合物和应用 |
EP3461822B1 (en) | 2016-07-11 | 2022-11-02 | Wuhan LL Science And Technology Development Co., Ltd. | Crystalline form of chemical compound, and preparation method, composition, and application thereof |
WO2018019300A1 (zh) | 2016-07-29 | 2018-02-01 | 武汉朗来科技发展有限公司 | 一种口服固体制剂及其应用 |
CN109803657B (zh) * | 2016-10-08 | 2022-07-29 | 武汉朗来科技发展有限公司 | 药物组合物 |
WO2018196860A1 (zh) | 2017-04-28 | 2018-11-01 | 武汉朗来科技发展有限公司 | 羧酸铵盐化合物、其晶型、无定形物及其制备方法 |
CN109305965B (zh) * | 2017-07-28 | 2021-03-16 | 武汉朗来科技发展有限公司 | 苯并咪唑衍生物制备及分析方法 |
CN109316451B (zh) * | 2017-07-31 | 2022-07-01 | 武汉朗来科技发展有限公司 | 治疗高血压和相关疾病的口服固体制剂 |
WO2019085983A1 (zh) * | 2017-11-03 | 2019-05-09 | 武汉朗来科技发展有限公司 | 低杂质含量苯并咪唑衍生物的制备方法 |
CN110237072B (zh) * | 2018-03-09 | 2022-03-25 | 武汉朗来科技发展有限公司 | 药物组合物的制备方法 |
CN110237071B (zh) | 2018-03-09 | 2022-03-22 | 武汉朗来科技发展有限公司 | 药物制剂及其应用 |
CN112745306A (zh) * | 2019-10-29 | 2021-05-04 | 华创合成制药股份有限公司 | 苯并咪唑类化合物及其制备方法和用途 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1079966A (zh) * | 1991-06-27 | 1993-12-29 | 武田药品工业株式会社 | 杂环化合物,其制备及应用 |
US5583141A (en) * | 1991-06-27 | 1996-12-10 | Takeda Chemical Industries, Ltd. | Heterocyclic compounds and their use as angiotensin antagonists |
CN1946717A (zh) * | 2004-02-25 | 2007-04-11 | 武田药品工业株式会社 | 苯并咪唑衍生物及其作为aⅱ受体拮抗剂的用途 |
CN102351853A (zh) * | 2011-08-29 | 2012-02-15 | 石药集团欧意药业有限公司 | 一种阿齐沙坦酯化合物、制备方法及其药物组合物 |
WO2012090043A1 (en) * | 2010-12-29 | 2012-07-05 | Jubilant Life Sciences Limited | Novel solid state forms of azilsartan medoxomil and preparation thereof |
WO2012107814A1 (en) * | 2011-02-08 | 2012-08-16 | Jubilant Life Sciences Limited | An improved process for the preparation of azilsartan medoxomil |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101151260B (zh) * | 2005-03-30 | 2011-06-29 | 武田药品工业株式会社 | 苯并咪唑衍生物及其作为血管紧张素ⅱ拮抗剂的用途 |
CN102766138B (zh) * | 2012-07-23 | 2017-10-24 | 温州市人民医院 | 一种阿齐沙坦的制备方法 |
CN103709154B (zh) * | 2012-09-28 | 2016-06-15 | 武汉朗来科技发展有限公司 | 苯并咪唑衍生物及其制备方法和医药用途 |
-
2013
- 2013-02-04 CN CN201310042669.2A patent/CN103709154B/zh active Active
- 2013-02-04 CN CN201510617905.8A patent/CN105237527B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1079966A (zh) * | 1991-06-27 | 1993-12-29 | 武田药品工业株式会社 | 杂环化合物,其制备及应用 |
US5583141A (en) * | 1991-06-27 | 1996-12-10 | Takeda Chemical Industries, Ltd. | Heterocyclic compounds and their use as angiotensin antagonists |
CN1946717A (zh) * | 2004-02-25 | 2007-04-11 | 武田药品工业株式会社 | 苯并咪唑衍生物及其作为aⅱ受体拮抗剂的用途 |
WO2012090043A1 (en) * | 2010-12-29 | 2012-07-05 | Jubilant Life Sciences Limited | Novel solid state forms of azilsartan medoxomil and preparation thereof |
WO2012107814A1 (en) * | 2011-02-08 | 2012-08-16 | Jubilant Life Sciences Limited | An improved process for the preparation of azilsartan medoxomil |
CN102351853A (zh) * | 2011-08-29 | 2012-02-15 | 石药集团欧意药业有限公司 | 一种阿齐沙坦酯化合物、制备方法及其药物组合物 |
Non-Patent Citations (1)
Title |
---|
心血管疾病新药阿奇沙坦酯的药理与临床评价;赵春艳,等;《中国新药杂志》;20111031;第20卷(第19期);第1831-1834页 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105237527A (zh) * | 2012-09-28 | 2016-01-13 | 武汉朗来科技发展有限公司 | 苯并咪唑衍生物及其制备方法和医药用途 |
Also Published As
Publication number | Publication date |
---|---|
CN103709154A (zh) | 2014-04-09 |
CN105237527A (zh) | 2016-01-13 |
CN105237527B (zh) | 2018-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103709154B (zh) | 苯并咪唑衍生物及其制备方法和医药用途 | |
CA2830742C (en) | Substituted oxanes as opioid receptor ligands and methods of using and making same | |
JP5990106B2 (ja) | 縮環化合物 | |
CN101163504A (zh) | 联合疗法 | |
WO1991019697A1 (en) | Pyridine derivative with angiotensin ii antagonism | |
EA026692B1 (ru) | Стимуляторы sgc | |
RU2233278C9 (ru) | Пиримидиноновые соединения, способ их получения и фармацевтическая композиция | |
KR20070045272A (ko) | 2-페닐피리딘 유도체 | |
JP2008019273A (ja) | 虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのat1−レセプターアンタゴニスト | |
JP2019182880A (ja) | 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の処置方法 | |
CN105153141B (zh) | 苯并咪唑衍生物及其制备方法和医药用途 | |
JP5290190B2 (ja) | イミダゾール−5−カルボン酸誘導体の塩、製造方法及びその医薬組成物 | |
WO2016145622A1 (zh) | 苯并咪唑衍生物及其制备方法和医药用途 | |
AU782393B2 (en) | Remedies for reperfusion injury containing integrin alphavbeta3 antagonist | |
CN107922448A (zh) | 一种氘代噻吩并哌啶衍生物、制备方法及其应用 | |
KR102651280B1 (ko) | 치환된 피리다진온류 화합물과 그 용도 | |
CN103420890B (zh) | 3-吡咯甲酸衍生物及其制备方法和用途 | |
WO2013155422A1 (en) | Methods of treating alopecia and acne | |
CN102796040B (zh) | 1,4-二取代哌嗪衍生物、其制备方法和用途 | |
CA2434829C (en) | New benzoylguanidine salt | |
CN107823208A (zh) | 吗啉类化合物在制备治疗和预防肾纤维化药物中的应用 | |
CN111662239B (zh) | 1,2,4-三唑类化合物及其制法和药物用途 | |
JPS6216417A (ja) | 虚血性心疾患・不整脈治療・予防剤 | |
CN102875566B (zh) | 具有抗胃溃疡作用的噻吩衍生物 | |
CN102875567B (zh) | 一类含哌嗪化合物、制备及用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: WUHAN QIRUI PHARMACEUTICALS CO., LTD. Effective date: 20150519 Owner name: WUHAN LANGLAI TECHNOLOGY DEVELOPMENT CO., LTD. Free format text: FORMER OWNER: WUHAN QIRUI PHARMACEUTICALS CO., LTD. Effective date: 20150519 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20150519 Address after: 430075 Wuhan hi tech Development Zone, Wuhan, Hubei, 666 hi tech Avenue, Wuhan national biological industry base research and Development Zone, East Lake, C2-2 Applicant after: Wuhan Lang Lai development in science and technology company limited Applicant after: Wuhan Qirui Pharmaceuticals Co., Ltd. Address before: 430223, East Lake New Technology Development Zone, Wuhan Miao District, Optics Valley City, Hubei Province Applicant before: Wuhan Qirui Pharmaceuticals Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210514 Address after: 430075 C2-2 Guanggu Biological City, 666 High-tech Avenue, Donghu New Technology Development Zone, Wuhan City, Hubei Province Patentee after: WUHAN LANGLAI TECHNOLOGY DEVELOPMENT Co.,Ltd. Address before: 430075 C2-2, R & D zone, Wuhan National biological industry base, No. 666, Gaoxin Avenue, Wuhan East Lake New Technology Development Zone, Wuhan City, Hubei Province Patentee before: WUHAN LANGLAI TECHNOLOGY DEVELOPMENT Co.,Ltd. Patentee before: QR PHARMACEUTICALS Ltd. |